Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks

被引：0
|
作者：
Orkin, C. [1 ]
DeJesus, E. [2 ]
Ramgopal, M. [3 ]
Crofoot, G. [4 ]
Ruane, P. [5 ]
LaMarca, A. [6 ]
Mills, A. [7 ]
Van der Cam, B. [8 ]
De Wet, J. [9 ]
Rockstroh, J. [10 ]
Lazzarin, A. [11 ]
Rijnders, B. [12 ]
Podzamczer, D. [13 ]
Thalme, A. [14 ]
Stoeckle, M. [15 ]
Chu, H. [16 ]
Porter, D. [16 ]
Liu, H. [16 ]
Cheng, A. [16 ]
Quirk, E. [16 ]
SenGupta, D. [16 ]
Cao, H. [16 ]
机构：
[1] Barts Hlth NHS Trust, London, England
[2] Orlando Immunol Ctr, Orlando, FL USA
[3] Midway Immunol & Res Ctr, Ft Pierce, FL USA
[4] Crofoot Res Ctr, Houston, TX USA
[5] Peter Jerome Ruane, Los Angeles, CA USA
[6] Therafirst Med Ctr, Ft Lauderdale, FL USA
[7] Mills Clin Res, Los Angeles, CA USA
[8] Clin Univ St Luc, Brussels, Belgium
[9] JJ de Wet, Vancouver, BC, Canada
[10] Bonn Univ Hosp, Bonn, Germany
[11] Osped San Raffaele, Milan, Italy
[12] Erasmus MC, Rotterdam, Netherlands
[13] Hosp Univ Bellvitge, Barcelona, Spain
[14] Karolinska Univ Hosp, Stockholm, Sweden
[15] Univ Hosp Basel, Basel, Switzerland
[16] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
来源：
HIV MEDICINE | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P20
引用
收藏
页码：21 / 21
页数：1
相关论文
共 50 条
  • [1] Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks
    Orkin, Chloe
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Van der Cam, Bernard
    De Wet, Joseph
    Rockstroh, Jurgen
    Lazzarin, Adriano
    Rijnders, Bart
    Podzamczer, Daniel
    Thalme, Anders
    Stoeckle, Marcel
    Porter, Danielle
    Liu, Hui
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [2] Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials
    Hagins, D.
    Orkin, C.
    Daar, E. S.
    Mills, A.
    Brinson, C.
    DeJesus, E.
    Post, F. A.
    Morales-Ramirez, J.
    Thompson, M.
    Osiyemi, O.
    Rashbaum, B.
    Stellbrink, H-J
    Martorell, C.
    Liu, H.
    Liu, Y-P
    Porter, D.
    Collins, S. E.
    SenGupta, D.
    Das, M.
    HIV MEDICINE, 2018, 19 (10) : 724 - 733
  • [3] Weight gain after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in HIV-suppressed patients
    Cicalini, S.
    Lorenzini, P.
    Grilli, E.
    Plazzi, M. M.
    De Zottis, F.
    Camici, M.
    Fusto, M.
    Gagliardini, R.
    Bellagamba, R.
    Antinori, A.
    HIV MEDICINE, 2021, 22 : 31 - 32
  • [4] Associations with weight change and patient-reported outcomes after switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
    Lowman, E.
    Unger, N.
    Hardigan, P. C.
    Lee, N.
    HIV MEDICINE, 2020, 21 : 20 - 20
  • [5] Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial
    Wiriyatanakorn, Sirichai
    Sungkanuparph, Somnuek
    OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (07):
  • [6] Weight and Metabolic Changes After Switching From Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) plus Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC plus DTG, and TDF/FTC/Efavirenz (EFV) to TDF/Lamivudine (3TC)/DTG
    Bosch, Bronwyn
    Akpomiemie, Godspower
    Chandiwana, Nomathemba
    Sokhela, Simiso
    Hill, Andrew
    McCann, Kaitlyn
    Qavi, Ambar
    Mirchandani, Manya
    Venter, Willem Daniel Francois
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (08) : 1492 - 1495
  • [7] Tolerability and treatment completion of tenofovir alafenamide/emtricitabine/rilpivirine (TAF/FTC/RPV) as HIV postexposure prophylaxis
    Chauveau, M.
    Secher, S.
    Allavena, C.
    Patoureau, M.
    Mercier, E.
    Jovelin, T.
    Blanchi, S.
    Michau, C.
    Hitoto, H.
    Drouin, H.
    Merrien, D.
    Perre, P.
    Fialaire, P.
    Raffi, F.
    Bonnet, B.
    HIV MEDICINE, 2019, 20 : 257 - 258
  • [8] SALIF trial: switching suppressed first-line patients to tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV) is non-inferior to TDF/FTC/efavirenz (TDF/FTC/EFV) and could be an alternative treatment option in LMICs
    Munderi, P.
    Were, E.
    Avihingsanon, A.
    Mbida, P. Abena Messomo
    Mohapi, L.
    Samba, B. M.
    Jansen, M.
    Mohammed, P.
    Sawyerr, G.
    Barnes, P.
    van Delft, Y.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [9] Dolutegravir/tenofovir/emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe as efavirenz/tenofovir/ emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes surveillance in Botswana
    Zash, R.
    Jacobson, D.
    Mayondi, G.
    Diseko, M.
    Makhema, J.
    Mmalane, M.
    Gaolathe, T.
    Petlo, C.
    Holmes, L.
    Essex, M.
    Lockman, S.
    Shapiro, R.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 105 - 106
  • [10] Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'
    Amiel, Corinne
    Schneider, Veronique
    Guessant, Sabine
    Hamidi, Mohammed
    Kherallah, Khadijah
    Lebrette, Marie-Gisele
    Chas, Julie
    Lependeven, Catherine
    Pialoux, Gilles
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (12) : 3335 - 3339
12345